Brett G. Charlton

Frenchs Forest
Sydney, Saudi Arabia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan-lysyl oxidase inhibitor PXS-6302 in mature scars.

A randomized, double-blind, placebo-controlled phase 1 trial of the topical pan-lysyl oxidase inhibitor PXS-6302 in mature scars.

Journal: Science translational medicine

Published: September 10, 2025

The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement.

The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement.

Journal: Scientific reports

Published: January 16, 2025

A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis.

A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis.

Journal: Haematologica

Published: December 24, 2024

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.

Journal: Nature cancer

Published: September 28, 2021

An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies.

An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies.

Journal: Clinical and translational medicine

Published: July 18, 2021

Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.

Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: October 16, 2020

Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.

Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: October 19, 2016

Limb proportions show developmental plasticity in response to embryo movement.

Limb proportions show developmental plasticity in response to embryo movement.

Journal: Scientific reports

Published: May 17, 2016

Optimising inhaled mannitol for cystic fibrosis in an adult population.

Optimising inhaled mannitol for cystic fibrosis in an adult population.

Journal: Breathe (Sheffield, England)

Published: August 26, 2015

Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.

Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.

Journal: Thorax

Published: September 24, 2014

Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.

Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.

Journal: The open respiratory medicine journal

Published: November 18, 2013

Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device.

Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device.

Journal: The open respiratory medicine journal

Published: November 18, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026